ArticleTranslational vision science & technology2020
Therapeutic Potential of Extracellular Vesicles for the Treatment of Corneal Injuries and Scars.
Article in Translational vision science & technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Extracellular Vesicles in Ophthalmology: From Natural Nanocarriers to Engineered Therapeutics.Bioengineering (Basel, Switzerland) · 2026Review
- Review
- Effect of Periplaneta americana Extract on Corneal Fibrosis and Epithelial Healing After Rabbit Lamellar Keratectomy.Translational vision science & technology · 2025Article
- Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies.Signal transduction and targeted therapy · 2025Review
- Review
- Exosomal microRNAs as potential biomarkers and therapeutic targets in corneal diseases.Molecular vision · 2024Review
- Extracellular vesicles as a new horizon in the diagnosis and treatment of inflammatory eye diseases: A narrative review of the literature.Frontiers in immunology · 2023Review
- Review
- Extracellular Vesicles in Corneal Fibrosis/Scarring.International journal of molecular sciences · 2022Review
- Targeted Drug Delivery to the Central Nervous System Using Extracellular Vesicles.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Human limbal epithelial stem cell regulation, bioengineering and function.Progress in retinal and eye research · 2021Review
- Limbal stem cell diseases.Experimental eye research · 2021Review
- Extracellular Vesicles in the Cornea: Insights from Other Tissues.Analytical cellular pathology (Amsterdam) · 2021Review
- The Need for Improved Therapeutic Approaches to Protect the Cornea Against Chemotoxic Injuries.Translational vision science & technology · 2020Article
- An Eye on Extracellular Vesicles: Trends and Clinical Translations in Vision Research.Ophthalmology scienceArticle
- Crosstalk among miR-29, α-SMA, and TGFβ1/β3 in melatonin-induced exosome (Mel-prExo) treated human limbal mesenchymal stem cells (hLMSCs): An insight into scarless healing of the cornea.BioFactors (Oxford, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Infection, trauma, and chemical exposure of the ocular surface can severely damage the cornea, resulting in visually significant stromal scars. Current medical treatments are ineffective in mitigating corneal scarring, and corneal transplantation is the only therapy able to restore vision in these eyes. However, because of a severe shortage of corneal tissues, risks of blinding complications associated with corneal transplants, and a higher rate of graft failure in these eyes, an effective and deliverable alternative therapy for the prevention and treatment of corneal scarring remains a significant unmet medical need globally. In recent years, the therapeutic potential of extracellular vesicles (EVs) secreted by cells to mediate cell-cell communication has been a topic of increasing interest. EVs derived from mesenchymal stem cells, in particular human corneal stromal stem cells, have antifibrotic, anti-inflammatory, and regenerative effects in injured corneas. The exact mechanism of action of these functional EVs are largely unknown. Therapeutic development of EVs is at an early stage and warrants further preclinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.